BioCentury
ARTICLE | Company News

La Jolla in $125M royalty financing for Giapreza

May 11, 2018 6:16 PM UTC

La Jolla Pharmaceutical Co. (NASDAQ:LJPC) said it will receive $125 million from HealthCare Royalty Partners (Stamford, Conn.) in exchange for up to $225 million through tiered royalty payments on worldwide net sales of Giapreza angiotensin II.

FDA approved the renin-angiotensin system peptide agonist in December to increase blood pressure in adults with septic or other distributive shock. In its 1Q18 financial results reported May 10, the company said Giapreza posted $809,000 in 1Q sales (see BioCentury, Dec. 22, 2017)...